Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 16 |
| Active Pipeline (Recruiting Now) | 10 (4) |
| Completed vs Stopped Early | 6 / 0 (0.0%) |
| Median Closed Actual Enrollment | 30 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| National Cancer Center Hospital East | Kashiwa, Chiba | 12 |
| National Cancer Center Hospital | Tokyo | 3 |
| Yokohama City University Medical Center | Yokohama | 3 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT05646511 | TNT of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer | Phase III | RECRUITING |
| NCT04288999 | Surgery Plus Chemo Versus Chemoradiotherapy Followed by Surgery Plus Chemo for Locally Recurrent Rectal Cancer | Phase III | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the National Cancer Center Hospital East Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.